Just want to share important information and help my frend - David Oreshin :
Dear friends! I am currently looking for an investor for Angelico Ventures www.angelicoventures.com as we are fully invested and would like to continue to follow our path to achieving our mission in making the world free of ageing and disease. If you share our mission and would like to help us but you can't invest we are grateful for any help with sales, marketing, PR, GR, HR, IR, media, programming, design, fundraising etc. We welcome new partners to join Angelico Ventures team for sweat equity and profit sharing.
As an alternative I am looking for a full time job with a large or well funded organization, start up, high net worth individual in any field of business that will allow me to make good money through achieving the company goals and objectives so one day I can come back to Angelico Ventures business and make the world free of ageing and disease.
David Yury Oreshin is the founder of the first in Russia and CIS life sciences investment bank, VC, PE company Angelico Ventures, co founder of Alvansa Limited - pharmaceutical holding backed by Gazprombank and UFG Private Equity, founder of Angelico Pharmaceuticals. CEO of the Russian subsidiary of CureLab Oncology.
Angelico Ventures is a venture capital investment company focused on cancer, heart disease, neurodegenerative diseases, ageing and other therapeutic areas worldwide.
Angelico Management Consulting brings the world’s leading management consulting practice in life sciences to life sciences companies and investors.
Angelico Investment Banking is focused on the development of the global life sciences industry by bringing together only the best life sciences companies and investors worldwide. Major deals include Gazprombank and UFG Private Equity $200M investment in Alvansa Limited, pharmaceutical holding focused on pharmaceutical industry consolidation in Russia. NauchTekhStroy Plus (joint venture subsidiary of Pharmstandard, Russia's leading domestic pharmaceutical company) $58M investment and strategic alliance deal with Affitech, world’s leading monoclonal antibody company focused on development of new cancer therapeutics.
Angelico Pharmaceuticals is focused on development, registration, sales and marketing of nutriceuticals, pharmaceuticals and biopharmaceuticals that are safe and effective against major age related diseases such as cancer, heart disease, neurodegenerative diseases and other diseases. The mission of Angelico Pharmaceuticals is to generate revenue to finance radical life extension by saving lives of people and improving the quality of life. All Angelico Pharmaceuticals products are focused on human life extension by preventing, treating and providing support to the patients during the treatment of major age related diseases.
Angelico Radical Life Extension is focused on ending ageing by fixing genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intracellular communication. Angelico Radical Life Extension is currently in R&D stage and is going to laser beam focus on one product for radical human life extension that will ve also active against certain types of cancers by the end of 2014. Angelico Radical Life Extension is planning to start animal trials of our first product for radical human life extension in 2015. After obtaining promising data from animal trials Angelico Radical Life Extension will apply for IND in USA and approval to conduct clinical trials in Russia. We plan to position our first product for radical human life extension on the pharmaceutical market as a cancer drug active against certain types of cancers with a highly positive side effect of radical life extension. This approach allows Angelico Radical Life Extension to develop our first product for radical human life extension using traditional approach to pre-clinical and clinical trials, registration, sales and marketing of a biopharmaceutical drug what is going to simplify product development, registration, market entry and growth.
To contact me please e-mail: y.oreshin@angelicoventures.com
No comments:
Post a Comment